Siemens Healthineers and Biogen Announce Agreement to Jointly Develop New MRI Tools for Multiple Sclerosis

Siemens Healthineers and Biogen announced today that the companies plan to jointly develop magnetic resonance imaging (MRI) applications with the intent of quantifying key markers of multiple sclerosis (MS) disease activity and progression. Biogen is a leading biotechnology company with a deep focus on neurological and autoimmune conditions, which for two decades has been at the forefront of delivering therapies to MS patients.
Source: eHealth News EU - Category: Information Technology Tags: Featured Siemens Business and Industry Source Type: news